Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Arrhythmia Pub Date : 2024-08-27 DOI:10.1002/joa3.13139

Shotaro Hiramatsu MD, Hiroyuki Osanai MD, Yuichiro Sakai MD, Yoshiki Sogo MD, Yuki Tanaka MD, Hikari Matsumoto MD, Shun Miyamoto MD, Kensuke Tagahara MD, Kenji Arai MD, Takashi Watanabe MD, Yusuke Sakamoto MD, Teruhiro Sakaguchi MD, PhD, Shioh Oguchi MD, Takahiro Kanbara MD, PhD, Yoshihito Nakashima MD, Hiroshi Asano MD, Masayoshi Ajioka MD

{"title":"Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban","authors":"Shotaro Hiramatsu MD, Hiroyuki Osanai MD, Yuichiro Sakai MD, Yoshiki Sogo MD, Yuki Tanaka MD, Hikari Matsumoto MD, Shun Miyamoto MD, Kensuke Tagahara MD, Kenji Arai MD, Takashi Watanabe MD, Yusuke Sakamoto MD, Teruhiro Sakaguchi MD, PhD, Shioh Oguchi MD, Takahiro Kanbara MD, PhD, Yoshihito Nakashima MD, Hiroshi Asano MD, Masayoshi Ajioka MD","doi":"10.1002/joa3.13139","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; <i>p</i> < 0.0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.</p>\n </section>\n </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"40 5","pages":"1126-1130"},"PeriodicalIF":2.2000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13139","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.13139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.

Methods and Results

The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; p < 0.0001).

Conclusions

Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受 15 毫克剂量埃多沙班治疗的非瓣膜性心房颤动患者体内抗因子 Xa 活性的分布情况

背景尚未完全阐明服用埃多沙班 15 毫克的非瓣膜性心房颤动（NVAF）患者体内抗因子 Xa 活性（AXA）的分布情况。方法和结果对服用埃多沙班 15 毫克的 19 名非瓣膜性心房颤动患者的 AXA 谷值和峰值进行了测量。我们将这些结果与服用埃多沙班 30 毫克的患者进行了比较。15 毫克组和 30 毫克组的 AXA 峰值差异显著（分别为 0.74 ± 0.40 IU/mL 对 1.25 ± 0.48 IU/mL；p < 0.0001）。结论接受埃多沙班 15 毫克治疗的患者的 AXA 峰值和谷值均明显低于接受埃多沙班 30 毫克治疗的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊